- Home
- TNGX vs SPOK Comparison
TNGX vs SPOK Comparison
Compare TNGX & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SPOK
- Stock Information
- Founded
- TNGX 2014
- SPOK 2004
- Country
- TNGX United States
- SPOK United States
- Employees
- TNGX N/A
- SPOK N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- TNGX Health Care
- SPOK Telecommunications
- Exchange
- TNGX Nasdaq
- SPOK Nasdaq
- Market Cap
- TNGX 351.2M
- SPOK 318.9M
- IPO Year
- TNGX N/A
- SPOK 1992
- Fundamental
- Price
- TNGX $5.63
- SPOK $17.83
- Analyst Decision
- TNGX Strong Buy
- SPOK Hold
- Analyst Count
- TNGX 6
- SPOK 1
- Target Price
- TNGX $12.20
- SPOK $15.00
- AVG Volume (30 Days)
- TNGX 3.4M
- SPOK 110.5K
- Earning Date
- TNGX 08-06-2025
- SPOK 07-23-2025
- Dividend Yield
- TNGX N/A
- SPOK 7.01%
- EPS Growth
- TNGX N/A
- SPOK N/A
- EPS
- TNGX N/A
- SPOK 0.77
- Revenue
- TNGX $40,990,000.00
- SPOK $139,038,000.00
- Revenue This Year
- TNGX N/A
- SPOK $2.26
- Revenue Next Year
- TNGX N/A
- SPOK $2.54
- P/E Ratio
- TNGX N/A
- SPOK $23.15
- Revenue Growth
- TNGX 10.09
- SPOK N/A
- 52 Week Low
- TNGX $1.03
- SPOK $13.55
- 52 Week High
- TNGX $12.02
- SPOK $18.29
- Technical
- Relative Strength Index (RSI)
- TNGX 77.32
- SPOK 65.72
- Support Level
- TNGX $4.80
- SPOK $16.41
- Resistance Level
- TNGX $5.63
- SPOK $18.29
- Average True Range (ATR)
- TNGX 0.52
- SPOK 0.38
- MACD
- TNGX -0.03
- SPOK 0.09
- Stochastic Oscillator
- TNGX 83.33
- SPOK 78.20
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.